Current therapeutic options in active moderate-to-severe thyroid-associated ophthalmopathy
DOI:
https://doi.org/10.2478/AMB-2023-0045Keywords:
thyroid-associated opthalmopathy, treatment, glucocorticoids, therapeutic responseAbstract
Active moderate-to-severe TAO is a disease, the treatment of which requires a multidisciplinary team, an individualized approach and strict follow-up, yet it is often suboptimal.
Recent knowledge about the pathogenesis of the disease and the randomized controlled trials conducted in recent years made it possible to use new therapeutic combinations and biological agents. The currently recommended fi rst-line therapy for active moderate-to-severe TAO is the combination of intravenous glucocorticoids (GCs) in moderate doses and mycophenolate or, in more severe cases, a high-dose GC treatment alone. There are several options for second-choice therapy, if needed: a new course with GCs, combination of orbital radiotherapy and GCs (preferably intravenous), cyclosporine and oral GCs, azathioprine and oral GCs, rituximab, tocilizumab or teprotumumab. The clinical manifestations of TAO should also be considered when choosing second-line treatment.
Thus, for example, teprotumumab best aff ects diplopia, orbital radiotherapy – visual disturbances and diplopia, while intravenous GCs, mycophenolate, cyclosporine, rituximab and tocilizumab – the infl ammatory manifestations of TAO. However, the question of the availability of the new drugs in routine clinical practice remains unsolved.
References
Hiromatsu Y, Eguchi H, Tani J, et al. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–360.
Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Front Endocrinol (Lausanne). 2020;11(November):1-10.
Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777-783.
Bartalena L, Marcocci C, Pinchera A. Graves ’ophthalmopathy: A preventable disease? Eur J Endocrinol. 2002;146(4):457-461.
Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest. 2004;27(3):216-220.
Krieger CC, Place RF, Bevilacqua C, et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab. 2016;101(6):2340-2347.
Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological Aspects of Graves‘ Ophthalmopathy. Biomed Res Int. 2019 Nov 12;2019:7453260.
Khong JJ, McNab A, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2015;100(1):142-150.
Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves’ Disease, and Thyroid-Associated Ophthalmopathy. Thyroid. 2008;18(9):953-958.
Bahn RS. Graves’ Ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves‘ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves‘ orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67.
Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4): 395-402.
Siderova M. Thyroid-associated ophthalmopathy. Varna: Steno, 2017, 63-72.
Lanzolla G, Vannucchi G, Ionni I, et al. Cholesterol Serum Levels and Use of Statins in Graves‘ Orbitopathy: A New Starting Point for the Therapy. Front Endocrinol (Lausanne). 2020;10(January):1-8.
Sabini E, Mazzi B, Profi lo MA, et al. High Serum Cholesterol is a Novel Risk Factor for Graves’ Orbitopathy: Results of a Cross-Sectional Study. Thyroid. 2018;28(3):386-394.
Ismailova DS, Fedorov AA, Grusha YO. Ocular surface changes in thyroid eye disease. Orbit. 2013;32(2):87-90.
Ujhelyi B, Gogolak P, Erdei A, et al. Graves’ Orbitopathy Results in Profound Changes in Tear Composition: A Study of Plasminogen Activator Inhibitor-1 and Seven Cytokines. Thyroid. 2012;22(4):407-414.
Laurance K, John P, Nadine F. The use of ACTH and cortisone in the treatment and in the diff erential diagnosis of malignant exophthalmos: a preliminary report. Ann Intern Med. 1953;38(5):913-918.
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;55:9-269.
Nagayama Y, Izumi M, Kiriyama T, et al. Intravenous Methylprednisolone Pulse Therapy. Acta Endocr (Copenh).1984; 116: 513-518
Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest. 2001;24(3):152-158.
Bromberg N, Romaldini J, Sgarbi J, et al. Pulse therapy in Graves’ ophthalmopathy: improvement of eye signs and ophtalmic immunoglobulins. AA Balkema Publ Hague, 1991.1991;353-357.
Romaldini J, Werner R, Farah C, et al. Active Graves’ ophthalmopathy (GO) treatment with prolonged methylprednisolone therapy. Thyroid 1993. 1993;3-10.
Matejka G, Vergès B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves’ ophthalmopathy. Horm Metab Res. 1998;30(2):93-8.
van Geest RJ, Sasim I V, Koppeschaar HPF, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: A prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229-237.
Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234-5240.
Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the Eff ectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves ’ Ophthalmopathy : Results of a Prospective, Single-Blind, Randomized Study. J Clin Endocrinol Metab. 2001;86(8):3562-3567.
Aktaran Ş, Akarsu E, Erbağci İ, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2006;61(1):45-51.
Bartalena L, Krassas GE, Wiersinga W, et al. Effi cacy and safety of three diff erent cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454-4463.
Bartalena L, Veronesi G, Krassas GE, et al. Does early response to intravenous glucocorticoids predict the fi nal outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest. 2017;40(5):547-553.
Owecki M, Sowiński J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy. Pharm World Sci. 2006;28(2):73-75.
Gursoy A, Cesur M, Erdogan MF, et al. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves’ ophthalmopathy. Endocrine. 2006;29(3):513-516.
Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid. 2007;17(4):357-362.
Marinò M, Morabito E, Altea MA, et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest. 2005;28(5):280-284.
Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto’s thyroiditis: Case report. Thyroid. 2004;14(8):631-634.
Marinól M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14(5):403-406.
Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid. 2000;10(6):521-524.
Lendorf ME, Rasmussen ÅK, Fledelius HC, et al. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid. 2009;19(12):1431-1432.
Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: Effi cacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320-332.
Gontarz-Nowak K, Szychlińska M, Matuszewski W, et al. Current Knowledge on Graves’ Orbitopathy. J Clin Med. 2020;10(1):16-20.
Bartalena L, Marcocci C, Pinchera A. Orbital Radiotherapy for Graves’ Ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):13-24.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’Ophthalmopathy : Reality and Perspectives. Endocr Rev. 2007;21(2):168-199.
Nakahara H, Noguchil S, Murakami N, et al. Graves Ophthalmopathy: MR Evaluation of 10-Gy versus 24-Gy Irradiation combined with Systemic Corticosteroids. Thera. 1996;196(3):857-862.
Pitz S, Kahaly GJ, Ro H, et al. Low- Versus High-Dose Radiotherapy for Graves’ Ophthalmopathy : A Randomized, Single Blind Trial. J Clin Endocrinol Metab. 2016;85(1):102–108.
Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1973;37(2):276-285.
Gorman C, Garrity J, Fatourechi V. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108(9):1523-1534.
Mourits MP, Van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebocontrolled study. Lancet. 2000;355(9214):1505-1509.
Gabrovski R, Hristosov K, Siderova M, et al. Co orbital radiotherapy in Graves’ opthlamopathy. Scripta scientifi ca medica. 2013;45(4):41-45.
Prummel MF, Berghout A, Wiersinga WM, et al. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ophthalmopathy. Lancet. 1993;342(8877):949-954.
Bartalena L, Marcocci C, Chiovato L, et al. Orbital Cobalt Irradiation combined with Systemic Corticosteroids for Graves’ Ophthalmopathy: Comparison with Systemic Corticosteroids Alone. J Clin Endocrinol Metab. 1983;56(6):1139-1144.
Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more eff ective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853-860.
Tanda ML, Bartalena L. Effi cacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857-3865.
Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117-123.
Oeverhaus M, Witteler T, Lax H, et al. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Eff ective Than Intravenous Steroids Alone in Patients with Graves’ Orbitopathy. Horm Metab Res. 2017;49(10):739-747.
Kim JW, Han SH, Son BJ, et al. Effi cacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(5):991-998.
Johnson JC, Parker JS, Eyre P. Graves’ Ophthalmopathy. J Am Vet Med Assoc. 2021;259(4):353-355.
Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2003;88(8):3561-3566.
Wakelkamp IMMJ, Tan H, Saeed P, et al. Orbital irradiation for Graves’ ophthalmopathy: Is it safe? A long-term follow-up study. Ophthalmology. 2004;111(8):1557-62.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118.
Ye X, Bo X, Hu X, et al. Effi cacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247-255.
Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287-298.
Orgiazzi J. Adding the Immunosuppressant Mycophenolate Mofetil to Medium-Dose Infusions of Methylprednisolone Improves the Treatment of Graves’ Orbitopathy. Clin Thyroidol. 2018;30(1):10-14.
Tosato G, Pike SE. Cyclosporin in Autoimmune Disease. Lancet. 1985;325(8434):909-911.
Bartalena L, Marcocci C, Pinchera A. Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997;11(3):521-536.
Weetman AP, McGregor AM, Ludgate M, et al. Cyclosporin improves Graves’ ophthalmopathy. Lancet. 1983;322(8):486-9.
Kahaly GJ, Schrezennmeir J, Krause Um Schweikert B, et al. Cyclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415-422.
Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321(20):1353-1359.
Ginter A, Migliori ME. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review. R I Med J. 2016;99(6):26-30.
El Fassi D, Nielsen CH, Hasselbalch H, et al. Treatment- resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709-710.
Salvi M, Vannucchi G, Campi I, et al. Effi cacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154(4):511-7.
Salvi M, Vannucchi G, Currò N, et al. Effi cacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431.
Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized Controlled Trial of Rituximab in Patients With Graves’ Orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441.
Salvi M, Vannucchi G, Introna N, et al. Small Dose of Rituximab for Graves’ Orbitopathy: New Insights Into the Mechanism of Action. Arch Ophtalmol. 2012;130(1):2012-2014.
Descotes J. Immunotoxicity of monoclonal antibodies. Landes Biosci. 2009;1(2):104-111.
Van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis.2013;72(9):1496-1502.
Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: The result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96(8):2386-2394.
Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2018;40(1):236-267.
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med.2017;376(18):1748-1761.
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352.
Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off -treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360-372.
Kumar S, Leontovich A, Coenen MJ. Gene Expression Profiling of Orbital Adipose Tissue From Patients With Graves’Ophthalmopathy: a Protein-1 in Orbital Adipogenesis. 2005;90(8):4730-4735.
Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fi broblasts from patients with Graves’ophthalmopathy. Thyroid. 2001;11(10):929-934.
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018;195:181-190.
Pérez-Moreiras JV, Álvarez-López A, Gómez EC. Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy. Ophthal Plast Reconstr Surg. 2014;30(2):162-167.
Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant Graves’ orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience. J Clin Med. 2021;10(4):1-18.
Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Antiil-6 receptor tocilizumab in refractory graves’ orbitopathy: National multicenter observational study of 48 patients. J Clin Med. 2020;9(9):1-15.
Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8-12.
Chalvatzis NT, Tzamalis AK, Kalantzis GK, et al Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: Two-center experience. Eur J Ophthalmol. 2014;24(6):953-959.
Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299-309.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
